TARDBP and frontotemporal dementia: Development of TDP-43 fluid and PET biomarkers is an active area of research [113–116], and may prove beneficial in amyotrophic lateral sclerosis (ALS)/FTD, limbic-predominant age-related TDP-43 encephalopathy (LATE), and in AD.